Recent searches
Search options
Administered by:
Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by #Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial
The Lancet Infectious DiseasesEfficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trialGiven the high efficacy and favourable safety profile, acoziborole holds promise in
the efforts to reach the WHO goal of interrupting HAT transmission by 2030.